Dual PPAR Agonist and Hyperlipidemia in PBC

CME

Investigational Dual PPAR Agonist, FXR Agonist With Fibrate, and Hyperlipidemia in People With PBC: Conference Coverage of AASLD

Physicians: Maximum of 0.25 AMA PRA Category 1 Credit

Released: December 07, 2023

Expiration: December 06, 2024

Marlyn J. Mayo
Marlyn J. Mayo, MD

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Your colleague asks about the investigational second-line PBC therapy elafibranor. Based on a recent phase III study, what would you say? Compared with placebo, addition of elafibranor to UDCA therapy was associated with: 

2.

I am familiar with PBC data from the AASLD 2023 conference, and I plan to translate these data into current or future management strategies.